This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Morgan, R. Articles by Pandha, H. S. Search for Related Content PubMed PubMed Citation Articles by Morgan, R. Articles by Pandha, H. S.

Antagonism of HOX/PBX Dimer Formation Blocks the In vivo Proliferation of Melanoma

¹ Postgraduate Medical School, University of Surrey, Guildford, United Kingdom and ² St. George's University of London, London, United Kingdom

Requests for reprints: Richard Morgan, Postgraduate Medical School, University of Surrey, Manor Park, Guildford GU2 7WG, United Kingdom. Phone: 44-1483-688618; Fax: 44-1483-688558; E-mail: r.morgan{at}surrey.ac.uk.

Malignant melanoma is a cancer that arises from melanocyte cells in a complex but well-studied process, and which can only be successfully treated prior to metastasis as it is highly resistant to conventional therapies. A number of recent reports have indicated that members of the HOX family of homeodomain-containing transcription factors are deregulated in melanoma, and may actually be required to maintain proliferation. In this report, we describe the use of a novel, cell-permeable antagonist of the interaction between HOX proteins and PBX, a second homeodomain-containing transcription factor that modifies HOX activity. This antagonist can block the growth of murine B16 cells and trigger apoptosis both in vitro and in vivo when administered to mice with flank tumors. [Cancer Res 2007;67(12):5806–13]